141 related articles for article (PubMed ID: 33652898)
21. Impact of COVID-19 on Canadian medical oncologists and cancer care: Canadian Association of Medical Oncologists survey report.
Gill S; Hao D; Hirte H; Campbell A; Colwell B
Curr Oncol; 2020 Apr; 27(2):71-74. PubMed ID: 32489248
[TBL] [Abstract][Full Text] [Related]
22. Recommendations for Recovery of the COVID-19 Pandemic-related Diagnostic, Screening, and Procedure Backlog in Ontario: A Survey of Healthcare Leaders.
Telesnicki TT; Simpson AN; de Mestral C; Baxter NN; Urbach DR; Gomez D
Clin Invest Med; 2024 Jun; 47(2):4-11. PubMed ID: 38958478
[TBL] [Abstract][Full Text] [Related]
23. The reality of virtual care: Implications for cancer care beyond the pandemic.
Rodin D; Lovas M; Berlin A
Healthc (Amst); 2020 Dec; 8(4):100480. PubMed ID: 33129178
[TBL] [Abstract][Full Text] [Related]
24. Global oncology pharmacy response to COVID-19 pandemic: Medication access and safety.
Alexander M; Jupp J; Chazan G; O'Connor S; Chan A
J Oncol Pharm Pract; 2020 Jul; 26(5):1225-1229. PubMed ID: 32408842
[TBL] [Abstract][Full Text] [Related]
25. Cancer care in East Africa amidst the Covid-19 pandemic.
Henke O
Int J Cancer; 2021 Sep; 149(6):1399-1400. PubMed ID: 33913167
[No Abstract] [Full Text] [Related]
26. Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance.
Weinkove R; McQuilten ZK; Adler J; Agar MR; Blyth E; Cheng AC; Conyers R; Haeusler GM; Hardie C; Jackson C; Lane SW; Middlemiss T; Mollee P; Mulligan SP; Ritchie D; Ruka M; Solomon B; Szer J; Thursky KA; Wood EM; Worth LJ; Yong MK; Slavin MA; Teh BW
Med J Aust; 2020 Jun; 212(10):481-489. PubMed ID: 32401360
[TBL] [Abstract][Full Text] [Related]
27. The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysis.
Clark JJ; Dwyer D; Pinwill N; Clark P; Johnson P; Hackshaw A
Lancet Oncol; 2021 Jan; 22(1):66-73. PubMed ID: 33253639
[TBL] [Abstract][Full Text] [Related]
28. Expanding Telemonitoring in a Virtual World: A Case Study of the Expansion of a Heart Failure Telemonitoring Program During the COVID-19 Pandemic.
Wali S; Guessi Margarido M; Shah A; Ware P; McDonald M; O'Sullivan M; Duero Posada J; Ross H; Seto E
J Med Internet Res; 2021 Jan; 23(1):e26165. PubMed ID: 33444153
[TBL] [Abstract][Full Text] [Related]
29. American Society of Clinical Oncology Position Statement on Addressing the Affordability of Cancer Drugs.
American Society of Clinical Oncology
J Oncol Pract; 2018 Mar; 14(3):187-192. PubMed ID: 29091534
[No Abstract] [Full Text] [Related]
30. Managing cancer care during the COVID-19 pandemic: brief report from a North African single center.
Benhima N; Kaakoua M; Rachidi SA; Fadli ME; Belbaraka R
Pan Afr Med J; 2020; 35(Suppl 2):127. PubMed ID: 33282082
[TBL] [Abstract][Full Text] [Related]
31. A deliberative framework to identify the need for real-life evidence building of new cancer drugs after interim funding decision.
Leung L; de Lemos ML; Kovacic L
J Oncol Pharm Pract; 2018 Dec; 24(8):584-598. PubMed ID: 28747103
[TBL] [Abstract][Full Text] [Related]
32. Uncertainty from COVID-19 delays progress on the road to value-based cancer care.
Neubauer M; Jones B
Am J Manag Care; 2020 Oct; 26(8 Spec No.):SP251-SP252. PubMed ID: 33395233
[TBL] [Abstract][Full Text] [Related]
33. Canadian Cancer Centre Response to COVID-19 Pandemic: A National and Provincial Response.
Rittberg R; Mann A; Desautels D; Earle CC; Navaratnam S; Pitz M
Curr Oncol; 2020 Dec; 28(1):233-251. PubMed ID: 33704191
[TBL] [Abstract][Full Text] [Related]
34. Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers.
MacLeod TE; Harris AH; Mahal A
Patient; 2016 Jun; 9(3):201-22. PubMed ID: 26370257
[TBL] [Abstract][Full Text] [Related]
35. Use of a Remote Oncology Pharmacy Service Platform for Patients With Cancer During the COVID-19 Pandemic: Implementation and User Acceptance Evaluation.
Chen ZJ; Liang WT; Liu Q; He R; Chen QC; Li QF; Zhang Y; Du XD; Pan Y; Liu S; Li XY; Wei X; Huang H; Huang HB; Liu T
J Med Internet Res; 2021 Jan; 23(1):e24619. PubMed ID: 33395398
[TBL] [Abstract][Full Text] [Related]
36. Can cancer care lead the way toward a value-based future?
Macmillan K
Am J Manag Care; 2019 Dec; 25(12 Spec No.):SP377-SP378. PubMed ID: 31860249
[No Abstract] [Full Text] [Related]
37. Supply chain capacity to respond to the COVID-19 pandemic in Ontario: Challenges faced by a health system in transition.
Snowdon AW; Wright A
Healthc Manage Forum; 2022 Mar; 35(2):53-61. PubMed ID: 35129402
[TBL] [Abstract][Full Text] [Related]
38. Seeking value as cancer drug costs soar.
Bender E
Cancer Discov; 2013 Aug; 3(8):833-4. PubMed ID: 23928760
[TBL] [Abstract][Full Text] [Related]
39. Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations.
Jenei K; Meyers DE
BMJ Open; 2023 Oct; 13(10):e066378. PubMed ID: 37844982
[TBL] [Abstract][Full Text] [Related]
40. Value-based payment models in oncology: will they help or hinder patient access to new treatments?
Shah S; Reh G
Am J Manag Care; 2017 Apr; 23(5 Spec No.):SP188-SP190. PubMed ID: 28665677
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
